Phase 3Completed
Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine (COVID-19)
A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia
- Sponsor
- PT Bio Farma (Industry)
- Enrollment
- 1,620 enrolled
- Conditions
- SARS-CoV2 Infection
- Interventions
- SARS-CoV-2 vaccine (inactivated); Placebo
- Ages
- adults
- Registry
- NCT04508075
Full record on ClinicalTrials.gov
From the registry
This phase III trial aims to assess the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (inactivated) and lot-to-lot consistency evaluation
Primary outcomes
- Incidence of laboratory-confirmed COVID-19 after the second dose
History
Last registry update
Study completion
Primary completion
Registered
Started